12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2022-05-28), Myovant Sciences's 12-1 Month Momentum % is -61.73%.
The industry rank for Myovant Sciences's 12-1 Month Momentum % or its related term are showing as below:
MYOV's 12-1 Month Momentum % is ranked worse than 68.52% of 1382
companies
in the Biotechnology industry
Industry Median: -44.50
vs MYOV: -61.73
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences 12-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Myovant Sciences 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.81(8.08%) Volume: 603,321 4:01PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
